3649 results for «414»
3649 results
TAVI: nightmare in the cathlab - Cardiac arrest, aortic root rupture & duct occluder
16 Nov 2025 – From PCR London Valves 2025
Explore critical complications encountered during TAVI procedures in this session, which highlights urgent scenarios such as cardiac arrest from calcific leaflet shift, aortic root rupture, and embolisation events. It also covers salvage techniques like TAVR-in-TAVR-in-SAVR in cardiogenic shock and management of acute left main occlusion with...
Curious mitral and tricuspid scenarios
16 Nov 2025 – From PCR London Valves 2025
This session presents a series of challenging and unusual clinical scenarios involving mitral and tricuspid valve disease. Topics include management of acute primary mitral regurgitation in high-surgical-risk patients, technical challenges in transcatheter mitral valve replacement (TMVR), and complex cases where cardiac rhythm disturbances interplay with valvular...
Challenging mitral TEER: overcoming access limitations and anatomical challenges
16 Nov 2025 – From PCR London Valves 2025
This session delves into the challenges of mitral transcatheter edge-to-edge repair (TEER), focusing on complex cases such as denied access, patch dehiscence-induced regurgitation, and functional mitral regurgitation due to amyloid cardiomyopathy. It also highlights innovative imaging approaches, including the use of transthoracic echocardiography as a rescue...
Challenging tricuspid TEER
16 Nov 2025 – From PCR London Valves 2025
This session focuses on the intricacies of transcatheter tricuspid edge-to-edge repair (TEER) addressing iatrogenic tricuspid regurgitation, failed surgical valve repair, and approaches for patients unsuitable for valve replacement. It also examines the management of multiple clip detachments and the procedural nuances required to navigate complex tricuspid...
Innvolution Healthcare reports one-year findings from the ALCHEMY study evaluating Eternia in 1000 patients at EuroPCR 2026
27 May 2026
Four-Year Outcomes from the EVOLUT Low Risk Trial
26 Oct 2023
Dejan Milasinovic provides his take on the EVOLUT Low Risk trial, presented by Michael I. Reardon at TCT Congress 2023. 4-year results reveal a continuing trend towards lower combined rates of all-cause mortality and disabling stroke with TAVI compared with surgical aortic valve replacement (SAVR)
Author
5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)
01 Apr 2025
Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.
Author
Transcatheter vs surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut Low Risk trial
05 Mar 2023
Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.
Author
Cardiac biomarkers in patients with asymptomatic severe aortic stenosis: primary biomarker analysis from the EARLY TAVR Trial
01 Apr 2025
Elad Asher provides his take on the primary biomarker analysis from the EARLY TAVR Trial presented by Brian R. Lindman at ACC.25 in Chicago.
Author
